


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/783,887
Filing Date	February 20, 2004
First Named Inventor	Shao Song Chu
Art Unit	1810-1626
Examiner Name	GrShameen
Attorney Docket Number	PC19146B

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
AS	AA	US 5,968,929	10-19-1999	Blythin, D., et al.	
	AB	US 6,114,365	09-05-2000	Pevarello, P., et al.	
	AC	US 6,460,202	10-08-2002	Nameche, L.	
	AD	US 6,462,069	10-08-2002	Reich, S., et al.	
	AE	US 6,555,539	04-29-2003	Reich, S., et al.	
	AF	US 6,566,363	05-20-2003	Chong, W., et al.	
	AG	US 6,620,828	09-16-2003	Chu, S., et al.	
AS	AH	US 2004/0176431	09-09-2004	Chong, W., et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
AS	AI	EP 816362A	01-07-1998	Taisho Pharmaceutical Co. Ltd.		
	AJ	WO 98/04536	02-05-1998	Otsuka Pharmaceutical Company, Limited		
	AK	WO 99/21845	05-06-1999	Agouron Pharmaceuticals, Inc.		
	AL	WO 99/24416	05-20-1999	Bristol-Myers Squibb Company		
	AM	WO 99/24035	05-20-1999	Bristol-Myers Squibb Company		
AS	AN	WO 99/65884	12-23-1999	Bristol-Myers Squibb Company		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/783,887
Filing Date	February 20, 2004
First Named Inventor	Shao Song Chu
Art Unit	1618 1626
Examiner Name	TBA G.S. Shamen
Attorney Docket Number	PC19146B

AS	AO	WO 99/65844	12-23-1999	Rhodia Chimie		
	AP	WO 00/17175	03-30-2000	Vertex Pharmaceuticals Incorporated		
	AQ	WO 00/26202	05-11-2000	Pharmacia & Upjohn S.P.A.		
	AR	WO 00/26203	05-11-2000	Pharmacia & Upjohn S.P.A.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS		ABELE, S., et al., "Oligomers Of β^2 And Of β^3 -HOMOPROLINE: What Are The Secondary Structures Of β -Peptides Lacking H-Bonds?," <i>Helvetica Chimica Acta</i> , 1999, 1539-1558, vol. 82.	
AT		ADAMS, J., et al., "Recent Progress Towards The Identification Of Selective Inhibitors Of Serine/Threonine Protein Kinases," <i>Current Opinion In Drug Discovery & Development</i> , 1999, 96-109, vol. 2, no. 2.	
AU		ANDERSON, Jr., A., et al., "The synthesis Of Azetidine-3-Carboxylic Acid," <i>J. Org. Chem.</i> , 1972, 3953-3655, vol. 37, no. 24.	
AV		BLEICHER, L., et al., "A Practical And Efficient Synthesis Of The Selective Neuronal Acetylcholine-Gated Ion Channel Agonist (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Malaeate (SIB-1508Y)," <i>J. Org. Chem.</i> , 1998, 1109-1118, vol. 63.	
AW		BOGESO, K., et al., "Enhanced D ₁ Affinity In A Series Of Piperazine Ring Substituted 1-Piperazino-3-Arylindans With Potential Atypically Antipsychotic Activity," <i>J. Med. Chem.</i> , 1995, 4380-4392, vol. 38.	
AX		BUOLAMWINI, J., et al., "Cell Cycle Molecular Targets In Novel Anticancer Drug Discovery," <i>Current Pharmaceutical Design</i> , 2000, 379-392, vol. 6.	
AY		CALDWELL, W., et al., "The Synthesis Of 2-Amino-5-Pyrimidinesulfonamide And Some Of Its Derivatives," <i>J. Amer. Chem. Soc.</i> , 1959, 5166-5167, vol. 81.	
AZ		CALDWELL, W., et al., "Substituted 2-Sulfonamido-5-Aminopyridines. II," <i>J. Amer. Chem. Soc.</i> , 1944, 1479-1484, vol. 66.	
BA		CHUNG, J., et al., "Conformationally Constrained Amino Acids. Synthesis And Optical Resolution Of 3-Substituted Proline Derivatives," <i>J. Org. Chem.</i> , 1990, 270-275, vol. 55.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

Application Number	10/783,887
Filing Date	February 20, 2004
First Named Inventor	Shao Song Chu
Art Unit	1646-1628
Examiner Name	Shao Song Chu
Attorney Docket Number	PC19146B

BB	COREY, E., et al., "Formation Of Olefins Via Pyrolysis Of Sulfonate Esters," <i>J. Org. Chem.</i> , 1989, 389-393, vol. 54.
BC	COSSY, J., et al., "Ring Expansion - Formation Of Optically Active 3-Hydroxypiperidines From Pyrrolidinemethanol Derivatives," <i>Eur. J. Org. Chem.</i> , 1999, 1693-1699.
BD	CREWS, C., et al., "Small-Molecule Inhibitors Of The Cell Cycle," <i>Current Opinion In Chemical Biology</i> , 2000, 47-53, vol. 4.
BE	DE COSTA, B., et al., "Synthesis And Biological Evaluation Of conformationally Restricted 2-(1-Pyrrolidinyl)-N-[2-(3,4-Dichlorophenyl)Ethyl]-N-Methylethylenediamines As Receptor Ligands. 1. Pyrrolidine, Piperidine, Homopiperidine, And Tetrahydroisoquinoline Classes," <i>J. Med. Chem.</i> , 1992, 4334-4343, vol. 35.
BF	DEWYNTER, G., et al., "Synthèse de "Sulfahydantoïnes" Chirales. Aspects Stéréochimiques Et Protection Régiospécifique," <i>Tetrahedron</i> , 1993, 65-76, vol. 49, no. 1.
BG	DONETTI, A., et al., "A Mild And Effective Two-Step Conversion Of Disubstituted Cyanamides To Secondary Amines," <i>J. Org. Chem.</i> , 1972, 3352-3353, vol. 37, no. 21.
BH	FISCHER, P., et al., "Inhibitors Of cyclin-Dependent Kinases As Anti-Cancer Therapeutics," <i>Current Medicinal Chemistry</i> , 2000, 1213-1245, vol. 7.
BI	FRY, D., et al., "Inhibitors Of cyclin-Dependent Kinases As Therapeutic Agents For The Treatment Of Cancer," <i>Current. Opin In. Oncologic, Endocrine & Metabolic. Investigtional Drugs</i> , 2000, 40-59, vol. 2, no. 1.
BJ	GARCIA-ECHEVERRIA, C., et al., "ATP Site-Directed Competitive And Irreversible Inhibitors Of Protein Kinases," <i>Med. Res. Rev.</i> , 2000, 28-57, vol. 20.
BK	GEWALD, V., et al., "4-Amino-thiazole," <i>Journal Für Praktische Chemie</i> , 1967, 97-104, vol. 35.
BL	GRAY, N., et al., "ATP-Site Directed Inhibitors Of Cyclin-Dependent Kinases," <i>Current Medicinal Chemistry</i> , 1999, 859-875, vol. 6.
BM	KARAMAN, R., et al., "Symmetrical And Unsymmetrical Quadruply Aza Bridged Closely Interspaced Cofacial Bis(5,10,15,20-tetraphenylporphyrin)s. 2. Synthesis, Characterization, And Conformational Effects Of Solvents," <i>J. Am. Chem. Soc.</i> , 1992, 4889-4898, vol. 114.
BN	KASHIMA, C., et al., "Preparation Of Sterically More Crowded 1,5-Disubstituted Imidazoles By The Regioselective N-Alkylation," <i>Heterocycles</i> , 1993, 433-440, vol. 35, no. 1.

EXAMINER: 	DATE CONSIDERED: 4/4/08
---	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard-ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/783,887
Filing Date	February 20, 2004
First Named Inventor	Shao Song Chu
Art Unit	1648-1626
Examiner Name	TBA-G. Shanmugan
Attorney Docket Number	PC19146B

BO	KEMPF, D., et al., "Symmetry-Based Inhibitors Of HIV Protease. Structure-Activity Studies Of Acylated 2,4-Diamino-1,5-Diphenyl-3-Hydroxypentane And 2,5-Diamino-1,6-Diphenylhexane-3,4-Diol," <i>J. Med. Chem.</i> , 1993, 320-330, vol. 36.
BP	KIRK, K., et al., "Facile Synthesis Of 2-Substituted Imidazoles," <i>J. Org. Chem.</i> , 1978, 4381-4383, vol. 43, no. 22.
BQ	KLOEK, J., et al., "An Improved Synthesis Of sulfamoyl Chlorides," <i>J. Org. Chem.</i> , 1976, 4028-4029, vol. 41, no. 25.
BR	LEWIS, F., et al., "Photophysical And Photochemical Behavior Of Intramolecular Styrene-amine Exciplexes," <i>J. Am. Chem. Soc.</i> , 1991, 3498-3506, vol. 113.
BS	MAGNUS, P., et al., "Synthesis Of The Vinblastine-like Antitumor Bis-Indole Alkaloid Navelbine Analogue Desethylidihydronevelbine," <i>J. Org. Chem.</i> , 1991, 1166-1170, vol. 56.
BT	MARKLEY, L., et al., "Antipicornavirus Activity Of Substituted Phenoxybenzenes And Phenoxy pyridines," <i>J. Med. Chem.</i> , 1986, 427-433, vol. 29.
BU	MC MAHON, G., et al., "Protein Kinase Inhibitors: Structural Determinants For Target Specificity," <i>Current Opinion In Drug Discovery & Development</i> , 1998, 131-146, vol. 1.
BV	MOSS, R., et al., "An Imidazole-Functionalized Phosphatidylcholine derivative: Nucleophilic Vesicles With Adjustable Reactivity," <i>J. Amer. Chem. Soc.</i> , 1987, 6209-6210, vol. 109.
BW	NAEGELI, C., et al., "2-Amino-Pyridin-5-Sulfonsäure-Amid Und Einige Abkömmlinge," <i>Helv. Chim. Acta.</i> , 1939, 1746-1756, vol. 21.
BX	NORRIS, T., et al., "Synthesis Of Trovafloxacin Using Various (1 α ,5 α ,6 α)-3-Azabicyclo[3.1.0]Hexane Derivatives," <i>J. Chem. Soc., Perkin Trans. 1</i> , 2000, 1615-1622.
BY	O'CONNELL, J., et al., "Convenient Synthesis Of Methyl 1-Methyl-2,4-Dibromo-5-Imidaolecarboxylate," <i>Synthesis</i> , 1988, 767-771.
BZ	OWENS, A., et al., "Cardiotonic Agents 4. Dimaprit analogues As Potential Cardiovascular Selective H ₂ -Agonists," <i>Eur. J. Med. Chem. Chem.</i> , 1988, 295-300, vol. 23.
CA	PAU, A., et al., "Synthesis Of 1-Methyl-4-(N-Aroyl)-Piperidinamides With Anti-Inflammatory And Analgesic Activities," <i>Farmaco</i> , 1998, 233-240, vol. 53.
CB	RONDESTVEDT, Jr., C., et al., "Unsaturated Sulfonic Acids. IV. Preparation And Properties Of α -Bromoalkenesulfonyl Chlorides," <i>J. Amer. Chem. Soc.</i> , 1954, 1926-1929, vol. 76.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10783,887
Filing Date	February 20, 2004
First Named Inventor	Shao Song Chu
Art Unit	1010 1576
Examiner Name	EBA
Attorney Docket Number	PC19146B

22	CC	ROSANIA, G., et al., "Targeting Hyperproliferative Disorders With Cyclin Dependent Kinase Inhibitors," <i>Expert Opinion On Therapeutic Patents</i> , 2000, 215-230, vol. 10, no. 2.
1	CD	SIELECKI, T., et al., "Cyclin-Dependent Kinase Inhibitors: Useful Targets In Cell Cycle Regulation," <i>Journal of Medicinal Chemistry</i> , 2000, 1-18, vol. 43, no. 1.
	CE	STERNFELD, F., et al., "Synthesis And Serotonergic Activity Of 3-[2-(Pyrrolidin-1-yl)Ethyl]Indoles: Potent Agonist For The h5-HT _{1D} Receptor With High Selectivity Over The h5-HT _{1B} Receptor," <i>J. Med. Chem.</i> , 1999, 677-690, vol. 42.
	CF	STOVER, R., et al., "Recent Advances In Protein Kinase Inhibition: current Molecular Scaffolds Used For Inhibitor Synthesis," <i>Current Opinion In Drug Discovery & Development</i> , 1999, 274-285, vol. 2.
	CG	STRAWN, L., et al., "Tyrosine Kinases In Disease: Overview Of Kinase Inhibitors As Therapeutic Agents And current Drugs In Clinical Trials," <i>Expert Opinion On Investigational Drugs</i> , 1998, 553-573, vol. 7.
	CH	TOLEDO, L., et al., "The Structure-Based Design Of ATP-Site Directed Protein Kinase Inhibitors," <i>Current Medicinal Chemistry</i> , 1999, 775-805, vol. 6.
	CI	VIOLA, A., et al., "Acetylenes As Potential Antarafacial Components In Concerted Reactions. Formatio Of Pyrroles From Thermolyses Of Propargylamines, Of A Dihydrofuran From A Propargylic Ether And Of An Ethylidenepyrrolidine From A β -Amino Acetylene," <i>J. Org. Chem.</i>
	CJ	WEBSTER, K., et al., "The Therapeutic Potential Of Targeting The Cell Cycle," <i>Exert. Opinion On Investigtional Drugs</i> , 1998, 865-887, vol. 7.
1	CK	WINN, M., et al., "2,4-Diarylpiperidine-3-Carboxylic Acids-Potent ET _A Selective Endothelin Receptor Antagonists. 1. Discovery Of A-127722," <i>J. Med. Chem.</i> , 1996, 1039-1048, vol. 39.
58	CL	ZHAO, R., et al., "Camptothecin And Minor-Groove Binder Hybrid Molecules: Synthesis, Inhibition Of Topoisomerase I, And Anticancer Cytotoxicity <i>in Vitro</i> ," <i>J. Med. Chem.</i> , 1997, 216-225, vol. 40.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.